National
Pentagon study leaks are aiding repeal effort
Media reports influencing fence-sitting senators: advocates
Capitol Hill observers say recently leaked details about the upcoming Pentagon study on “Don’t Ask, Don’t Tell” are having a positive influence on the effort to repeal the military’s gay ban.
Meanwhile, some repeal advocates anticipate that congressional hearings will be held on the study before action on repeal is wrapped up.
Alex Nicholson, executive director of Servicemembers United, said “it’s undeniable” that the leaked findings were “extremely helpful” to repeal advocates.
“Whether or not it’ll take us across the tipping point, I don’t know,” he added. “That’s anybody’s guess. It’s undeniable that it moves us more in that direction, but people disagree on where that tipping point is.”
R. Clarke Cooper, executive director of the Log Cabin Republicans, said media reports on the Pentagon working group study are still too recent to properly assess their impact on convincing Republicans to vote in favor of repeal. Still, he said he’s confident the findings will “bring in additional votes.”
“It’s certainly a bolster to the case we’ve been making with Republican lawmakers and their staff that the study is beneficial, it’s very thorough and the terms that Defense Secretary Robert Gates laid out are very clear,” Cooper said.
Repeal advocates said they hope the leaks, which were published in the Washington Post, will bolsters efforts in the Senate to pass the fiscal year 2011 defense authorization bill, which contains language to end “Don’t Ask, Don’t Tell.” A previous vote to move forward with the legislation in September didn’t meet the 60-vote threshold to make it to the Senate floor.
On Wednesday evening, the Washington Post reported that the results of a survey sent to 400,000 U.S. service members over the summer as part of the Pentagon working group’s efforts will reveal that more than 70 percent of respondents think the effect of ending “Don’t Ask, Don’t Tell” would be positive, mixed or nonexistent. A similar report was published Thursday in The New York Times.
These survey results reportedly led study authors to conclude that objections to gays serving openly in the U.S. military would drop after the implementation of open service. The deadline for completing the study and delivering it to Defense Secretary Robert Gates is Dec. 1.
According to the Washington Post, the working group report is about 370 pages long and is divided into two sections. The first section examines whether ending “Don’t Ask, Don’t Tell” will harm unit readiness or morale. The second part offers a plan for ending enforcement of the law. This second section is not meant to serve as the military’s official instruction manual on the issue, but could be used as such if military leaders agreed.
A Democratic aide, who spoke to the Blade on condition of anonymity, said reporting on the Pentagon working group study is infusing pro-repeal efforts “with a newfound energy.”
“Some pro-repeal senators are already touting the findings in discussions with their colleagues, in hopes of galvanizing sufficient support for repeal,” the aide said. “The repeal effort was being hampered by the lack of a completed Pentagon study, but with the study complete — and showing that repeal can be implemented — the anti-repeal effort suddenly seems disingenuous.”
Joe Solmonese, president of the Human Rights Campaign, called on the Pentagon to make the working group report public.
“With the Senate soon turning its attention again to military policy, the results of the Pentagon review should be made available as soon as possible so undecided Senators are well informed,” Solmonese said.
But the leaked findings have already riled social conservatives seeking to keep the ban on open service in place. On Thursday, Tony Perkins, president of the Family Research Council, noted he’s previously taken exception to the Pentagon working group report because he said the scope of the study isn’t appropriate.
“We have criticized this study from the outset because the [Pentagon working group] was forbidden to explore the central question before the country — not how to implement a repeal of the current law, but whether doing so is in the best interest of the armed forces,” Perkins said. “The surveys of service members and their spouses, which were conducted as part of this process shared the same flaw, since they never asked, ‘Do you believe the current law should be overturned?’”
Perkins called on Gates to direct the Pentagon’s inspector general to investigate the source of the leaks and said the leaks to media outlets have “seriously damaged the credibility” of the Pentagon’s review process.
Reporting on the Pentagon study could influence a number of key U.S. senators who have said they want to see the results of the survey before acting on legislation.
A Republican aide, who spoke on condition of anonymity, said the media reports on the Pentagon’s study are having a “positive” impact on influencing those lawmakers to support “Don’t Ask, Don’t Tell” repeal.
“Members who have said let’s wait for the report don’t have much to turn to when the report comes out supportive,” the aide said.
Nicholson said senators who’ve “hinged their vote on the outcome of this review” could vote for a motion to proceed on the defense authorization bill, then use the report to guide their decision on a potential amendment related to the “Don’t Ask, Don’t Tell” language after the bill comes to the floor.
“Given the fact that the way it’s set up is that they can take a vote on cloture before Thanksgiving or before the report comes out … then that, in theory, doesn’t conflict with their stance because they’ll get to take a vote on ‘Don’t Ask, Don’t Tell’ after the report comes out,” Nicholson said.
The Center for American Progress has identified 10 senators and senators-elect who’ve said they want the Pentagon to complete the study before Congress acts on the military’s gay ban.
Among them are Sens. Scott Brown (R-Mass.), Lindsey Graham (R-S.C.), Judd Gregg (R-N.H.), John McCain (R-Ariz.), Mark Pryor (D-Ark.), Olympia Snowe (R-Maine), George Voinovich (R-Ohio) and Jim Webb (D-Va.). The newly elected senators who, because of state election laws, are expected to take their seats during the lame duck session — Mark Kirk of Illinois and Joe Manchin of West Virginia — have also made statements along those lines.
Aubrey Sarvis, executive director of the Servicemembers Legal Defense Network, said there have been “no concrete changes yet” on the positions of the senators and senators-elect since the publication of the media reports on the Pentagon’s findings.
“Overall, I think it’s a positive to have the stories out there and now we need to see the report itself,” Sarvis said.
The Blade contacted all of those senators and senators-elect for comment. Only Webb’s office immediately responded. The Virginia senator has previously withheld support for repeal and said he wants to wait for the Pentagon survey results.
According to Webb’s office, the senator’s position hasn’t yet changed. Will Jenkins, a Webb spokesperson, said the senator “is awaiting the release of the final report so he can review the official survey result.”
But Nicholson said Webb’s support for repeal is of limited importance because the Virginia Democrat already voted in favor of cloture on the defense authorization when Senate leadership tried to move it to the floor in September.
“Webb voted for cloture, so it really doesn’t even matter,” Nicholson said. “If we can just get past that hurdle, we don’t need everybody on board for the motion to strike vote. So in theory, we don’t really need Webb.”
One open question is whether the results of the Pentagon working group report would prompt hearings in the Senate Armed Services Committee and whether those hearings will prevent the Senate from moving forward with the defense authorization bill and “Don’t Ask, Don’t Tell” repeal.
The Democratic aide said it’s “unknown” whether the report would prompt hearings in the committee, although such a scenario is possible.
“But McCain, for example, could try to force hearings … and [Senate Armed Services Committee Chair Carl] Levin could relent to McCain’s request,” the aide said.
Nicholson said he believes there will “definitely be a call for hearings” as a result of the Pentagon working group’s findings.
Lawmakers like McCain, Nicholson said, will want hearings to “tear the review apart” and “discredit everything they’ve done and just try to find ways to poke holes in the eventuality that’s coming.” Still, he said moderate senators would want hearings for different reasons.
“I would expect that they would also support hearings, but I think it remains to be seen whether or not they would let their desire for hearings obstruct moving forward on this right now,” Nicholson said.
Nicholson noted the “Don’t Ask, Don’t Tell” language provides for a 60-day review period that is “supposed to be exactly for” congressional review, such as hearing testimony. The review period begins after President Obama, the defense secretary and the chairman of the Joint Chiefs of Staff certify the U.S. military is ready for repeal.
Sarvis said the decision about whether to hold hearings is up to Levin and said he “may schedule hearings this year and next year.” Still, Sarvis said the hearings wouldn’t necessarily delay congressional action on “Don’t Ask, Don’t Tell.”
“I don’t know that the hearings would necessarily get in the way of floor consideration because committee hearings are usually held in the mornings, and the mornings in the Senate is not a time when the Senate usually is voting,” Sarvis said.
UPDATE: In a statement Friday, Geoff Morrell, a Pentagon spokesperson, said Gates is “very concerned and extremely disappointed” that Pentagon sources have leaked information about the “Don’t Ask, Don’t Tell” report and said he’s launching an investigation into the matter.
“The Secretary strongly condemns the unauthorized release of information related to this report and has directed an investigation to establish who communicated with the Washington Post or any other news organization without authorization and in violation of Department policy and his specific instruction,” Morrell said.
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Using movement to boost your mental health during holidays
